Abstract:Abstract Background: Abnormal telomere maintenance has been significantly implicated in tumor development and progression. Telomere length has recently emerged as a promising predictor for the risk of various cancers including hepatocellular carcinoma (HCC). Nonetheless, no studies have been reported on measuring telomere length in circulating cell-free DNA samples as a non-invasive biomarker of cancer risk. Method: In this nested case-control study, we used real-time quantitative PCR to determine the relative telomere length (RTL) in serum DNA samples from 140 hepatitis B virus (HBV)-related HCC (HBV-HCC) cases and 280 frequency-matched cancer-free HBV controls, and evaluated the associations between RTL and HBV-HCC risk, as well as RTL and HBV-cirrhosis risk in a sub-population of 100 HBV-cirrhosis cases and 100 matched HBV controls. Results: We found that HBV-HCC cases had a significantly longer RTL (median, 0.31; range, 0.02-2.31) versus HBV controls (median, 0.20; range, 0.01-1.60) (P=0.003). Using the median RTL value in controls as the cutoff point, individuals with longer RTLs exhibited a significantly increased risk of HCC compared to those with short RTLs in an univariate logistic regression analysis (odds ratio [OR]=1.55, 95% confidence interval [CI] 1.02-2.33, P=0.038). However, the strength of this association attenuated after multivariate adjustment (OR=1.40, 95% CI 0.90-2.19, P=0.132). In a quartile analysis, a significant dose-response relationship was noted in the univariate analysis (P trend=0.017) which was attenuated in the multivariate analysis (P trend=0.079). Further analyses revealed that the significant association between serum RTL and HCC risk was only evident in non-cirrhotic (OR=3.54, 95% CI 1.58-7.93 P=0.002), but not in cirrhotic (OR=0.95, 95% CI 0.55-1.64, P=0.860) HBV patients. Additionally, a significant difference (P=0.004) of RTL distribution was observed between cirrhotic and non-cirrhotic HBV controls. We further analyzed the association of RTL with liver cirrhosis risk. Using patients with short RTL as reference, we found long RTL conferred a significantly increased risk of HBV-related cirrhosis in univariate and multivariate analyses with unadjusted OR of 2.70 (95% CI 1.50-4.88, P=0.001) and 2.73 (95% CI 1.51-4.93, P=0.001), respectively. Further tertile and quartile analysis showed a significant dose-response relationship (P trend <0.001 for both) in both univariate and multivariate analysis. Conclusions: Collectively, our data suggested that RTL in circulating cell-free serum DNA could potentially be used as a novel non-invasive biomarker for non-cirrhotic HBV-HCC and HBV-related cirrhosis. Prospective cohort studies are warranted to further validate this finding and assess its clinical significance in HCC prevention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4462. doi:1538-7445.AM2012-4462

Telomerase Gene Mutations Are Associated with Cirrhosis Formation

The role of telomeres and telomerase in cirrhosis and liver cancer

Mutation Analysis of Novel Human Liver-Related Putative Tumor Suppressor Gene in Hepatocellular Carcinoma

Telomere shortening is a prognostic factor in chronic hepatitis C virus infection

Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target

Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status

Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors

Telomerase Reverse Transcriptase Mutations In Plasma Dna In Patients With Hepatocellular Carcinoma Or Cirrhosis: Prevalence And Risk Factors

Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data

Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations

Telomere Length in Circulating Serum DNA As a Novel Non-Invasive Biomarker for Cirrhosis: a Nested Case-Control Analysis.

Telomere Length Variation in Tumor Cells and Cancer-Associated Fibroblasts: Potential Biomarker for Hepatocellular Carcinoma.

Liver disease and transplantation in telomere biology disorders: An international multicenter cohort

Recent advances in understanding telomere diseases

Telomere length in hepatocellular carcinoma and paired adjacent non-tumor tissues by quantitative PCR.

Abstract 4462: Relative Telomere Length in Circulating Serum DNA As a Novel Non-Invasive Biomarker in Hepatocarcinogenesis

Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver

Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

Telomerase activity and telomere length in human hepatocellular carcinoma

Clinical mutations in the TERT and TERC genes coding for telomerase components induced oxidative stress, DNA damage at telomeres and cell apoptosis besides decreased telomerase activity